
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2013

IMPRIMIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

001-35814

(Commission
File Number)

45-0567010

(IRS Employer
Identification No.)

**12626 High Bluff Dr. Ste 150
San Diego, CA**

(Address of principal executive offices)

92130

(Zip Code)

Registrant's telephone number, including area code: **(858) 704-4040**

N/A

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01. Regulation FD Disclosure

Attached as Exhibit 99.1 to this Item 7.01 is a presentation that is being used by the management of Imprimis Pharmaceuticals, Inc. (the “Company”) in meetings describing the Company.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits**(d) Exhibits**

99.1 Presentation dated December 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMPRIMIS PHARMACEUTICALS, INC.

Dated: December 16, 2013

By: /s/ Andrew R. Boll

Name: Andrew R. Boll

Title: Vice President, Accounting and Public Reporting

EXHIBIT INDEX

99.1 Presentation dated December 2013

Welcome

Imprimis Pharmaceuticals, Inc.
Investor Update

December 16, 2013

Robert J. Kammer

Chairman, Imprimis Pharmaceuticals, Inc.

A large, stylized white outline of a chemical structure, possibly a hexagonal ring or a complex molecule, is positioned on the right side of the slide. It consists of several interconnected hexagonal shapes.


Mark L. Baum

CEO, Imprimis Pharmaceuticals, Inc.

Imprimis Accomplishments

Corporate Vision and 2014 Outlook

Imprimis Strategic Positioning



2013 Drivers of Healthcare



Health Care Reform

Drug Quality and Security Act (DQSA)

(Law Passed Last Month—11/27/13)

US Healthcare Market focused on:

1. Maintaining quality
2. Lowering costs
3. Getting everyone covered

We believe Congress recognized the opportunity to “federalize” the compounding pharmacy market AND address:

- The physician and consumer demand for personalized/customized medicine
- The ever-growing drug shortage list
- Facility quality standards (i.e. Meningitis 2012)

New realities require a new way of thinking


The Compounding Pharmacy Model



- Approx. 7,500 US compounding pharmacies governed by *state pharmacy laws*
- Compounding pharmacists make patient-specific medications under physician's treatment directives
- Repurpose the more than 7,800 FDA approved generic drugs to build new medicines



Bottom-Up Approach to Drug Development



Personalized Medicine *Today*

The Prescriber-Pharmacist-Patient Triad



- Physicians and Pharmacists understand patient needs
- Pharmacists customize medications for specific patient needs
- The Triad can identify opportunities to help large numbers of patients



Key Accomplishments

- **Recapitalized the business**
- **Continued to develop innovative relationships with pharmacists and physicians**
- **Formalized our ARM process to evaluate innovation**
- **Acquired IP in four key therapeutic areas: Ophthalmology, Wound Management, Urology and Pain.**
- **Created Ophthalmology Division**
 - **Announced plans to become a commercial company in Ophthalmology in 1H2014**
 - **Hired Industry veteran—John Saharek—who has already begun building out the sales team**



Gary Seelhorst


Vice President, Corporate Development
Imprimis Pharmaceuticals, Inc.

Pipeline Assets and ARM Process


How Our Business Works



Patient-Focused Model



Asset Review Methodology (ARM™)



John Saharek

VP, Commercialization Ophthalmology Division
Imprimis Pharmaceuticals, Inc.


“Go Dropless” – Ophthalmic Division Overview

Ophthalmic Opportunity

- > 3.5 Million cataract procedures annually
- ~ \$1 Billion market for pre-op and post-op therapeutics
 - Drops make up a significant portion of this market
- Patient challenges with Drop Therapy
 - Compliance
 - Cost
- Doctor challenges with Drop Therapy
 - Staff Time
 - Patient Counseling
- **Imprimis Pharmaceuticals “Dropless Thera**
 - Proprietary Compound Formulations
 - Provided as part of the surgical procedure
 - Patient friendly
 - Staff friendly
 - Cost effective




Creating a Market for TriMoxi



Developing the Market

- Build Imprimis ophthalmology commercial team
- Identify and recruit Key Opinion Leaders (KOLs)
- Develop a pricing and access strategy
- Create clear concise messaging
- Implement a broad communication strategy
 - Ophthalmic Symposiums & Congresses
 - Podium Presentations
 - Trade Journal Articles
- Develop training materials
- Set up the state-by state distribution network



2014 Outlook

2014 Outlook

- Compounding pharmacy facilities strategy
- Sell, make and distribute ophthalmology products
- Launch business divisions in wound management, urology and pain
- Begin scaling business to establish national footprint
- Continue to hire key employees



Condensed Balance Sheet

(Unaudited and Abbreviated)

ASSETS	September 30, 2013
Current Assets	
Cash and short term investments	\$ 16,877,683
Other assets	525,609
TOTAL ASSETS	<u>\$ 17,403,292</u>
LIABILITIES AND STOCKHOLDERS' EQUITY	
Accounts payable and other accruals	\$ 1,058,545
TOTAL LIABILITIES	<u>1,058,545</u>
Stockholder's Equity	
Common stock, \$0.001 par value, 395,000,000 shares authorized, 8,970,364 shares issued and outstanding	8,970
Additional paid-in capital	46,201,042
Deficit accumulated during the development stage	(29,865,265)
TOTAL STOCKHOLDERS' EQUITY	<u>16,344,747</u>
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	<u>\$ 17,403,292</u>



Company Overview

- Approx. \$17M in cash as of September 30, 2013
- Nominal debt; no preferred instruments
- Near, mid and long term catalysts
- Strong key strategic / innovative relationships
- Experienced management team to execute



Questions?

Thank You!
Happy Holidays

